Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population

News provided by

Feb 26, 2021, 07:15 ET

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market. Find out how in this thorough report.

Comprehensive panels, genomic profiling, high-risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

Key Topics Covered:

Cancer Panel Market - Strategic Situation Analysis & COVID Update

Guide for Executives, Marketing, Sales and Business Development Staff
Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition
1.1 What are Cancer Gene Panels and Profiling?
1.2 The Sequencing Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 A Spending Perspective on Clinical Laboratory Testing
1.5.1 An Historical Look at Clinical Testing

2. Market Overview
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Instrumentation Supplier
2.1.4 Distributor and Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Office Labs
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Oncogenomics
2.2.1 Carcinogenesis
2.2.2 Chromosomes, Genes and Epigenetics
2.2.2.1 Chromosomes
2.2.2.2 Genes
2.2.2.3 Epigenetics
2.2.3 Cancer Genes
2.2.4 Germline vs Somatic
2.2.5 Gene Panels, Single Gene Assays and Multiplexing
2.2.6 Genomic Profiling
2.2.7 The Comprehensive Assay
2.2.8 Changing Clinical Role
2.2.9 The Cancer Screening Market Opportunity
2.3 Cancer Management vs. Diagnosis
2.3.1 The Role of Risk Assessment
2.3.2 Diagnosis
2.3.3 Managing
2.3.4 Monitoring
2.4 Phases of Adoption - Looking into The Future
2.5 Structure of Industry Plays a Part
2.5.1 Hospital Testing Share
2.5.2 Economies of Scale
2.5.2.1 Hospital vs. Central Lab
2.5.3 Physician Office Lab's
2.5.4 Physician's and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 Level of Care
3.1.2 Companion Dx
3.1.3 Immuno-oncology
3.1.4 Liability
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 State of knowledge
3.2.2 Genetic Blizzard.
3.2.3 Protocol Resistance
3.2.4 Regulation and coverage
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Single Cell Genomics Changes the Picture
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magnetoresistance based assay

4. Cancer Panels & Profiles Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section

Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Metastatic Cancer Markers Identified in Clinical WGS Study
Stitch Bio Bets on CRISPR Tech
Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
Progress, Challenges in Liquid Biopsy Reimbursement
Israeli Startup Curesponse Raises $6M
Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
Germline Results Guides Precision Therapy in Advanced Cancer
FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
Labs Reporting Cancer Risk Mutations from Tumor Testing
Users Begin Integrating Genomics Data for Clinical Decision Support
Fujitsu Improves Efficiency in Cancer Genomic Medicine
Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
Universal Genetic Testing for All Breast Cancer Patients
Exact Sciences buys Genomic Health
Multi-Gene Liquid Biopsy Breast Cancer Panel
Thrive to Develop Earlier Detection of Multiple Cancer Types
New Gene Panel Identifies High Risk Prostate Cancer
Guardant Health Liquid Biopsy Test to be Covered by EviCore
Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
Natera Commercializes Tumor Whole Exome Sequencing from Plasma
Inivata Completes 39.8M Series B Funding Round
Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
Biodesix Acquires Integrated Diagnostics
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

5. Profiles of Key Players

Abbott Diagnostics
AccuraGen Inc
Acuamark Diagnostics
Admera Health, LLC
Agena Bioscience, Inc
Agilent
Almac Diagnostics
Amoy Diagnostics Co., Ltd.
Anchor Dx
ANGLE plc
ApoCell, Inc.
ArcherDx, Inc
Asuragen
AVIVA Biosciences
Baylor Miraca Genetics Laboratories
Beckman Coulter, Inc.
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocartis
Biocept, Inc
Biodesix Inc
BioFluidica
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc
Bio-Techne
Bioview
Blueprint Genetics
Bolidics
Boreal Genomics
Caris Molecular Diagnostics
CellMax Life
Cepheid (now Danaher)
Chronix Biomedical
Circulogene
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp
CytoTrack
Datar Cancer Genetics Limited
Diagenode Diagnostics
Diagnologix LLC
Enzo Life Sciences, Inc
Epic Sciences
Epigenomics AG
Eurofins Scientific
Exosome Diagnostics
Exosome Sciences
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
Fulgent Genetics
GeneFirst Ltd.
Genetron Health (Beijing) Co., Ltd
Genomic Health
GILUPI Nanomedizin
Grail, Inc.
Guardant Health
HansaBiomed
HeiScreen
Helomics
Horizon Discovery 224 iCellate
Illumina
Incell Dx
Inivata
Invitae Corporation
Integrated Diagnostics
Janssen Diagnostics
Loxo Oncology
MDNA Life SCIENCES, Inc
MDx Health
Menarini Silicon Biosystems
Millipore Sigma
Miltenyi Biotec
miR Scientific
Molecular MD
Myriad Genetics/Myriad RBM
NantHealth, Inc.
Natera
NeoGenomics
New Oncology
Novogene Bioinformatics Technology Co., Ltd.
Oncocyte
OncoDNA
Oxford Nanopore Technologies
Perkin Elmer
Personal Genome Diagnostics
PrecisionMed
Promega
Qiagen Gmbh
Quidel
Rarecells SAS
RareCyte
Resolution Biosciences, Inc
Roche Molecular Diagnostics
Screencell
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc
SRI International
Sysmex Inostics
Tempus Labs, Inc
Thermo Fisher Scientific Inc.
Thrive Earlier Detection
Trovagene
Volition

6. The Global Market for Cancer Gene Panels and Profiles
6.1 Global Market Overview by Country
6.2 Global Market by Cancer Type - Overview
6.3 Global Market Germline & Somatic - Overview

7. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer
7.1 Comprehensive Panels & Profiles
7.2 Breast Cancer Gene Testing
7.3 Colorectal Cancer Gene Testing
7.4 Gynecological Cancer Gene Testing
7.5 Blood Cancer Gene Testing
7.6 Prostate Cancer Gene Testing
7.7 Lung Cancer Gene Testing
7.8 Other Cancer Gene Testing

8. Global Cancer Gene Testing Markets - Germline and Somatic
8.1 Global Market Somatic
8.2 Global Market Germline

9. Potential Market Opportunity Sizes
9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal
9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
9.3 Potential Market Size - Cancer Diagnosis
9.4 Potential Market Size - Therapy Selection

Appendices

United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
FDA Approved Human Genetic Tests
Pharmacogenomic Biomarkers in Drug Labeling

For more information about this report visit https://www.researchandmarkets.com/r/dyohsq

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets